UK utility weights for the EORTC QLU-C10D

被引:46
作者
Norman, Richard [1 ]
Mercieca-Bebber, Rebecca [2 ,3 ]
Rowen, Donna [4 ]
Brazier, John E. [4 ]
Cella, David [5 ]
Pickard, A. Simon [6 ]
Street, Deborah J. [7 ]
Viney, Rosalie [8 ]
Revicki, Dennis [2 ]
King, Madeleine T. [2 ]
机构
[1] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia
[2] Univ Sydney, Fac Sci, Sch Psychol, Sydney, NSW, Australia
[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[4] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[7] Univ Technol Sydney, Cl1ERE, Sydney, NSW, Australia
[8] Patient Ctr Res, Bethesda, MD USA
基金
英国医学研究理事会;
关键词
cancer; discrete choice experiment; health state valuation; utility; DISCRETE-CHOICE EXPERIMENT; PREFERENCE-BASED MEASURE; HEALTH STATES; INSTRUMENT; VALUATION; QLQ-C30; IMPACT; VALUES; QALYS;
D O I
10.1002/hec.3950
中图分类号
F [经济];
学科分类号
02 ;
摘要
The EORTC QLU-C10D is a new multi-attribute utility instrument derived from the widely used cancer-specific quality of life questionnaire, EORTC QLQ-C30. It contains 10 dimensions (physical functioning, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems), each with four levels. The aim of this study was to provide U.K. general population utility weights for the QLU-C10D. A U.K. online panel was quota-sampled to align the sample to the general population proportions of sex and age (>= 18 years). The online valuation survey included a discrete choice experiment (DCE). Each participant was asked to complete 16 choice-pairs, each comprising two QLU-C10D health states plus duration. DCE data were analysed using conditional logistic regression to generate utility weights. Data from 2,187 respondents who completed at least one choice set were included in the DCE analysis. The final U.K. QLU-C10D utility weights comprised decrements for each level of each health dimension. For nine of the 10 dimensions (all except appetite), the expected monotonic pattern was observed across levels: Utility decreased as severity increased. For the final model, consistent monotonicity was achieved by merging inconsistent adjacent levels for appetite. The largest utility decrements were associated with physical functioning and pain. The worst possible health state (the worst level of each dimension) is -0.083, which is considered slightly worse than being dead. The U.K.-specific utility weights will enable cost-utility analysis (CUA) for the economic evaluation of new oncology therapies and technologies in the United Kingdom, where CUA is commonly used to inform resource allocation.
引用
收藏
页码:1385 / 1401
页数:17
相关论文
共 50 条
  • [31] The EORTC QLU-C10D distinguished better between cancer patients and the general population than PROPr and EQ-5D-5L in a cross-sectional study
    Doehmen, Annika
    Obbarius, Alexander
    Kock, Milan
    Nolte, Sandra
    Sidey-Gibbons, Christopher J.
    Valderas, Jose M.
    Rohde, Jens
    Rieger, Kathrin
    Fischer, Felix
    Keilholz, Ulrich
    Rose, Matthias
    Klapproth, Christoph Paul
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2025, 177
  • [32] Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values
    van Gelder, Thomas
    Mulhern, Brendan
    Schoormans, Dounya
    Husson, Olga
    Lourenco, Richard de Abreu
    QUALITY OF LIFE RESEARCH, 2020, 29 (06) : 1483 - 1494
  • [33] The Cancer-Specific Health Economic Measure QLU-C10D is Valid and Responsive for Assessing Health Utility in Patients with Thyroid Cancer
    Pilz, Micha J.
    Seyringer, Simone
    Singer, Susanne
    Ioannidis, Georgios
    Sykiotis, Gerasimos P.
    Arraras, Juan I.
    Husson, Olga
    Iakovou, Ioannis
    Fanetti, Giuseppe
    Fuehrer, Dagmar
    Inhestern, Johanna
    Kiyota, Naomi
    Locati, Laura Deborah
    Pinto, Monica
    Gama, Ricardo Ribeiro
    King, Madeleine T.
    Norman, Richard
    Gamper, Eva M.
    THYROID, 2024, 34 (11) : 1356 - 1370
  • [34] Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States
    Gamper, Eva-Maria
    Holzner, Bernhard
    King, Madeleine T.
    Norman, Richard
    Viney, Rosalie
    Nerich, Virginie
    Kemmler, Georg
    VALUE IN HEALTH, 2018, 21 (08) : 958 - 966
  • [35] Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values
    Thomas van Gelder
    Brendan Mulhern
    Dounya Schoormans
    Olga Husson
    Richard De Abreu Lourenço
    Quality of Life Research, 2020, 29 : 1483 - 1494
  • [36] Development of an EORTC-8D Utility Algorithm for Sri Lanka
    Kularatna, Sanjeewa
    Whitty, Jennifer A.
    Johnson, Newell W.
    Jayasinghe, Ruwan
    Scuffham, Paul A.
    MEDICAL DECISION MAKING, 2015, 35 (03) : 361 - 370
  • [37] Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy
    Bulamu, Norma B.
    Vissapragada, Ravi
    Chen, Gang
    Ratcliffe, Julie
    Mudge, Louise A.
    Smithers, B. Mark
    Isenring, Elizabeth A.
    Smith, Lorelle
    Jamieson, Glyn G.
    Watson, David, I
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2021, 19 (01)
  • [38] Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France
    Pilz, Micha J.
    Seyringer, Simone
    Nerich, Virginie
    King, Madeleine T.
    Norman, Richard
    Gamper, Eva M.
    PHARMACOECONOMICS, 2025,
  • [39] Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities
    Soare, Ioana-Alexandra
    Leeuwenkamp, Oscar
    Longworth, Louise
    PHARMACOECONOMICS-OPEN, 2021, 5 (04) : 715 - 725
  • [40] Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin's lymphoma
    Xu, Richard Huan
    Zhao, Zuyi
    Pan, Tianxin
    Monteiro, Andrea
    Gu, Hongfei
    Dong, Dong
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, : 671 - 682